Dermatology and Therapy最新文献

{"title":"Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis.","authors":"Richard B Warren, Anne Weiss, Jakob Felding, Morten O A Sommer","doi":"10.1007/s13555-025-01371-9","DOIUrl":"10.1007/s13555-025-01371-9","url":null,"abstract":"<p><strong>Introduction: </strong>Orismilast is a novel oral selective inhibitor of phosphodiesterase 4B and 4D subtypes (PDE4B/D) in clinical development for treatment of atopic dermatitis (AD) and other inflammatory skin conditions. Herein, we describe a pharmacokinetic/pharmacodynamic (PK/PD) analysis comparing predicted exposure data of orismilast and apremilast in AD patients and place these data in the context of their IL-13 secretion data generated in a human whole-blood assay.</p><p><strong>Methods: </strong>A PK/PD assessment of orismilast and apremilast in AD was performed. In a human whole blood assay, the levels needed to inhibit IL-13 production were measured for orismilast and apremilast head-to-head. These data were then contextualized with simulated exposure of clinically relevant doses of the two drugs.</p><p><strong>Results: </strong>The analysis shows that orismilast has potential to significantly inhibit IL-13 production at all three clinical doses trialed in AD (20 mg bid, 30 mg bid, and 40 mg bid) as the drug has a predicted C_average plasma concentration exceeding the IL-13 IC₉₀ value of the human whole-blood assay and a predicted C_min above the IL-13 IC₅₀ value. Apremilast, in contrast, is predicted to reach C_average plasma concentrations below the IL-13 IC₅₀ value for both doses (30 mg bid and 40 mg bid) and only exceeding the IL-13 IC₅₀ value at peak concentrations for the highest dose.</p><p><strong>Conclusion: </strong>The outcome of the analysis supports the observed clinical effect of orismilast in patients with AD and could explain the lack of efficacy of apremilast in the same indication.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"831-839"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease Burden and Treatment-Seeking Behaviour of Adults with Atopic Dermatitis in Singapore: An Online Cross-Sectional Survey.","authors":"Yik Weng Yew, Malvin Kang, Sharanya Jois, Adrien Gras, Christian Apfelbacher","doi":"10.1007/s13555-025-01379-1","DOIUrl":"10.1007/s13555-025-01379-1","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic systemic inflammatory skin disease with a notably high prevalence in Singapore. Despite available treatments, a significant proportion of patients remain untreated, highlighting a critical need to understand treatment-seeking behaviours and address the multi-faceted disease burden.</p><p><strong>Methods: </strong>An online survey was conducted among 344 adult patients and caregivers answering on behalf of patients to obtain data on clinical impact and quality-of life (QoL), current treatment goals, management, financial impact and treatment-seeking behaviours. This study analysed the differences between patients with different AD severity using data initially collected in Excel and processed in SPSS.</p><p><strong>Results: </strong>AD patients in Singapore face challenges like self-consciousness due to appearance (38%), treatment costs (36%) and the need for additional skincare (34%), with severe AD patients significantly more affected by these issues. Key symptoms like skin dryness (61%), itchiness (56%) and red/scaly skin (48%) worsen with disease severity. AD's impact on patients intensifies with severity, with 100% of severe AD patients rating their condition as 'very serious', correlating with a higher Dermatology Life Quality Index (DLQI) score. Management strategies for AD flare-ups include lifestyle changes (53%) and home remedies (48%). Financial burden is considerable, averaging US dollars (USD) 1368 per month, with 82% perceiving it as 'extreme', affecting treatment adherence.</p><p><strong>Conclusion: </strong>The study underscores the significant burden and impact on QoL faced by adult AD patients in Singapore. It highlights the necessity for targeted research on economic impacts and treatment behaviours in specific groups and the urgent need for effective interventions to enhance QoL, particularly for those with severe AD.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"997-1008"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Conjunctivitis and Keratitis Among Individuals with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab in the United States: a Cohort Study in Routine Care Based on Healthcare Claims.","authors":"Jessica M Franklin, Andrea F Marcus, Ihtisham Sultan, Ashley Howell, Sarah-Jo Sinnott, Jeannette Green, Stephen Ezzy, Robert Gately, Rachel E Sobel, Florence T Wang","doi":"10.1007/s13555-025-01367-5","DOIUrl":"10.1007/s13555-025-01367-5","url":null,"abstract":"<p><strong>Introduction: </strong>In clinical trials of patients with atopic dermatitis (AD), conjunctivitis and keratitis occurred more frequently with dupilumab than placebo. Studies using real-world data have also shown a higher incidence with dupilumab but did not use validated algorithms to identify the population and outcomes. The objective of this study was to investigate the incidence of conjunctivitis and keratitis among patients with moderate-to-severe AD treated with dupilumab relative to dupilumab-naïve patients in a real-world setting using validated algorithms.</p><p><strong>Methods: </strong>A retrospective observational cohort study was conducted in an insurance claims database using validated algorithms for moderate-to-severe AD and ocular outcomes. Initiators of dupilumab were identified and propensity score (PS) matched with dupilumab-naïve patients with moderate-to-severe AD. Incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for conjunctivitis and keratitis during follow-up were estimated using Poisson regression.</p><p><strong>Results: </strong>Among 13,790 patients in the moderate-to-severe AD study population, 2175 dupilumab initiators and 2189 dupilumab-naïve patients were included in the analysis. Dupilumab was associated with an increased risk of conjunctivitis (IRR = 1.86 [95% CI 1.51-2.30]) and keratitis (IRR = 4.06 [95% CI 1.70-9.68]) compared to patients with moderate-to-severe AD not receiving dupilumab. The cumulative 1-year risk of conjunctivitis was 15.8% and 8.4% in the dupilumab and dupilumab-naïve cohorts, respectively; the cumulative 1-year risk of keratitis was 1.3% and 0.2%, respectively.</p><p><strong>Conclusion: </strong>Study findings are consistent with safety data from clinical trials and existing literature. However, a few keratitis events were observed, and post hoc analyses suggested residual confounding might be present. The known benefit-risk profile for dupilumab remains unchanged.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"889-901"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.","authors":"Yan Zhao, Litao Zhang, Liming Wu, Xinsuo Duan, Chao Ji, Rong Xiao, Mingkai Ji, Lunfei Liu, Bin Yang, Guohong Hu, Yanyan Feng, Jianjian Zhu, Jianguo Li, Yangfeng Ding, Haomin Huang, Qinghong Zhou, Yuyu Xu, Jianzhong Zhang","doi":"10.1007/s13555-025-01368-4","DOIUrl":"10.1007/s13555-025-01368-4","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease. 611, a humanized monoclonal antibody, selectively targets the interleukin (IL)-4 receptor alpha, thereby inhibiting the signaling of both interleukin (IL)-4 and IL-13. This phase 2 study aimed to evaluate the efficacy and safety of 611 in Chinese adults with moderate-to-severe AD.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled phase 2 study was conducted between October 2022 and September 2023. Eligible patients with moderate-to-severe AD were randomly assigned in a 1:1:1 ratio to receive 611 at a dose of either 300 mg (loading dose of 600 mg) every 2 weeks (Group A) or 300 mg (loading dose of 600 mg) every 4 weeks (Group B), or placebo every 2 weeks for 16 weeks, followed by an 8-week follow-up period. The primary efficacy endpoint was the proportion of patients achieving at least a 75% reduction in the Eczema Area and Severity Index (EASI-75) score at week 16. The safety and pharmacodynamics were also assessed.</p><p><strong>Results: </strong>After 16 weeks of treatment, 60.0% of patients in Group A and 48.8% in Group B achieved EASI-75, both significantly higher than the placebo group (15.6%, p < 0.01). Additionally, 611 at both doses significantly improved the Investigator's Global Assessment (IGA) scores, peak pruritus numerical rating scale (NRS), and other efficacy endpoints. Patients receiving 611 demonstrated significant reductions in serum thymus activation-regulated chemokine (TARC) and total serum immunoglobulin E (IgE) levels. The incidence of treatment-emergent adverse events (TEAEs) was similar across all dosage groups. The most common 611-related TEAE is upper respiratory tract infections. No new safety concerns were identified.</p><p><strong>Conclusion: </strong>611 demonstrated a high efficacy and a favorable safety profile in patients with moderate-to-severe AD.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT05544591.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"857-867"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining Predictive Factors for Permanent Chemotherapy-Induced Alopecia: Trichoscopy, Reflectance Confocal Microscopy and Histopathology Study on 77 Patients.","authors":"Michela Starace, Victor Desmond Mandel, Marco Ardigo, Miriam Anna Carpanese, Federico Quadrelli, Francesca Pampaloni, Kaleci Shaniko, Aurora Alessandrini, Francesca Bruni, Alfredo Rossi, Maria Caterina Fortuna, Gemma Caro, Norma Cameli, Martina Silvestri, Gabriella Fabbrocini, Maria Carmela Annunziata, Mariateresa Cantelli, Maria Vastarella, Daniela Rubino, Claudio Zamagni, Giovanni Pellacani, Bianca Maria Piraccini","doi":"10.1007/s13555-025-01378-2","DOIUrl":"10.1007/s13555-025-01378-2","url":null,"abstract":"<p><strong>Introduction: </strong>Literature about trichoscopy of permanent chemotherapy-induced alopecia (pCIA) is still scarce, while no data were published regarding reflectance confocal microscopy (RCM). The aim of our study is to monitor the different phases of chemotherapy-induced alopecia development with trichoscopy and RCM, in order to identify predictor factors for permanent alopecia.</p><p><strong>Methods: </strong>This multicentre, prospective, observational study evaluated patients with cancer who were candidates for chemotherapy with a drug implicated in pCIA development. Patients were followed for the next 2 years after recruitment.</p><p><strong>Results: </strong>A total of 77 patients were enrolled. Six months after the discontinuation of chemotherapy in all patients with pCIA, trichoscopic examination revealed a diffuse presence of multiple yellow dots, the persistence of regrowing hairs, and an increase degree of miniaturization in comparison to baseline. RCM detected the permanence of inflammatory cells over time, especially around the adnexal structures, which led to the appearance of fibrosis and alteration of the normal rimming.</p><p><strong>Conclusions: </strong>Trichoscopy and RCM allowed one to detect the different phases of chemotherapy-induced alopecia development. The following predictor factors for pCIA were identified: a positive history of cyclophosphamide- and taxane-based chemotherapy; a diffuse presence of multiple yellow dots at trichoscopy; onset and persistence of a diffuse inflammatory infiltrate at RCM.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"869-887"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study.","authors":"Stephan Weidinger, Tobias Schadeck, Felix Jacobs, Ansgar Weyergraf, Dariusch Mortazawi, Tobias Hagemann, Fatima Abousamra, Thomas Mosch, Bjoern Fritz, Felix Lauffer","doi":"10.1007/s13555-025-01373-7","DOIUrl":"10.1007/s13555-025-01373-7","url":null,"abstract":"<p><strong>Introduction: </strong>Phase 3 clinical trials have demonstrated robust efficacy and favorable safety of upadacitinib for the treatment of atopic dermatitis (AD). However, real-world data are still sparse. The objectives of this study were to assess the effectiveness and safety of real-world treatment with upadacitinib in patients with moderate-to-severe AD.</p><p><strong>Methods: </strong>UP-TAINED is an ongoing German prospective, multicenter, observational study in adolescents and adults with moderate-to-severe AD treated with upadacitinib 15 or 30 mg once daily, according to local labeling. Effectiveness (primary endpoint; measured with the Atopic Dermatitis Control Tool [ADCT]) and safety are assessed over 2 years. Reported here are 1-year results from an interim analysis.</p><p><strong>Results: </strong>Data on 351 patients were included in the effectiveness analysis. At 12 weeks, 71.0% of patients had achieved disease control (ADCT total score < 7); at 1 year, this rate was 70.9%. An Eczema Area and Severity Index (EASI) ≤ 3 was achieved by 60.6% of patients after 4 weeks and 68.1% after 1 year of upadacitinib treatment. Of 186 patients with moderate-to-severe facial eczema at baseline and 142 patients with moderate-to-severe hand eczema at baseline, 60.8% (101/166) and 63.8% (83/101) achieved clear or almost clear skin in those respective body regions after 4 weeks of upadacitinib treatment. Of the 380 patients included in the safety analysis, 163 patients reported 426 adverse events (AEs), most classified as mild (59.7%) or moderate (34.6%). The most common AEs were (worsening of) AD, acne, and COVID-19. No major cardiovascular AEs, venous thromboembolism, or malignancies were reported.</p><p><strong>Conclusions: </strong>Upadacitinib was well tolerated, and the majority of patients with moderate-to- severe AD receiving upadacitinib in real-world clinical practice achieved stringent treatment goals with early and up to 1-year disease control attained, particularly in difficult-to-treat areas such as hand and face.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, NCT05139836.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"919-931"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palmoplantar Pustulosis as an Immune-Mediated Inflammatory Disease with a Possible Relevance of Th17 Cell Plasticity: A Narrative Review.","authors":"Tadashi Terui, Masamoto Murakami, Yukari Okubo, Koremasa Hayama, Hideki Fujita","doi":"10.1007/s13555-025-01382-6","DOIUrl":"10.1007/s13555-025-01382-6","url":null,"abstract":"<p><p>Palmoplantar pustulosis (PPP) is an immune-mediated inflammatory disease (IMID) of the skin that causes the formation of sterile pustules on the palms and soles. The clinical course of PPP is variable, with some patients having persistent skin lesions and others having lesions that wax and wane repeatedly. PPP has been treated with drugs such as those used for plaque psoriasis. The efficacy of biologics targeting the interleukin (IL)-23-helper T (Th)17 axis is not as conspicuous in PPP as in plaque psoriasis. Traditionally, CD4⁺ Th cell subsets have been defined by the expression of a small number of cytokines; however, recent advances in immunology have shown that some Th cell subsets can express cytokines of other Th subsets in response to changes in the environment. Recent studies have suggested the involvement of unique Th17 cells with Th2 cell characteristics in the pathogenesis of PPP. Thus, the insufficient efficacy of biologics targeting the IL-23-Th17 axis in PPP raises the question of whether Th17 cell plasticity is involved in the pathogenesis of PPP. In this review, we discuss the complexity of PPP pathogenesis with some speculation, compare the new knowledge obtained by other IMIDs or their mouse models with that of PPP elucidated thus far, and contribute to the development of future research.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"797-810"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years.","authors":"Veronique Gaudet, Irina Turchin, Charles W Lynde, Virginie Kelly, Dusan Sajic, Shazia Hassan, Belinda Yap, Maxime Barakat, Vimal H Prajapati","doi":"10.1007/s13555-025-01369-3","DOIUrl":"10.1007/s13555-025-01369-3","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis, a chronic inflammatory skin disease, affects approximately one million Canadians, with plaque psoriasis (PsO) being the most common subtype. While brodalumab has shown efficacy and safety in phase III clinical trials, Canadian real-world evidence remains limited. This retrospective cohort study aims to report on the real-world outcomes of Canadian patients with PsO who initiated treatment with brodalumab within the 4-year period following its approval by Health Canada.</p><p><strong>Methods: </strong>Data from patients with PsO initiating brodalumab treatment in the Canadian patient support program between July 1, 2018 and June 30, 2022 were analyzed. The primary objective evaluated the proportion of patients achieving a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) at selected time windows. Secondary and exploratory objectives included assessing the 90% reduction in PASI score (PASI 90), changes from baseline in mean PASI, body surface area (BSA), and Dermatology Life Quality Index (DLQI) scores, as well as treatment persistence.</p><p><strong>Results: </strong>A total of 2482 patients (58.5% male; mean age 51.0 years) were included, with over half being biologic-naïve (56.9%). In a subset of patients with baseline and at least one follow-up data, 66.1% and 53.2% achieved PASI 90 and PASI 100, respectively, within the first 3 months. These rates were sustained, with 68.1% and 52.2% achieving PASI 90 and PASI 100, respectively, beyond 24 months. Significant improvements from baseline were observed for PASI, BSA, and DLQI scores, and these improvements were maintained over time. Among all patients, the 1-year persistence rate was 73.4%.</p><p><strong>Conclusions: </strong>This study provides valuable insights into the profile of patients treated with brodalumab in Canada. While the rapid and sustained skin clearance, as well as improvements in PASI, BSA, and DLQI scores, support the therapeutic benefits of brodalumab beyond clinical trials, further research on long-term effectiveness and safety is warranted.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"949-962"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.","authors":"April W Armstrong, Leon Kircik, Linda Stein Gold, Bruce Strober, Claudia H M C De Oliveira, John Vaile, Ying-Ming Jou, Carolin Daamen, Thomas Scharnitz, Mark Lebwohl","doi":"10.1007/s13555-025-01362-w","DOIUrl":"10.1007/s13555-025-01362-w","url":null,"abstract":"<p><strong>Introduction: </strong>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the USA and other countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. In POETYK PSO-1 and PSO-2, deucravacitinib was superior to placebo and apremilast and well tolerated in patients with plaque psoriasis. Patients who completed PSO-1/PSO-2 could enroll in the POETYK long-term extension (LTE) trial. This analysis evaluates the effects of deucravacitinib on laboratory parameters.</p><p><strong>Methods: </strong>POETYK PSO-1 and PSO-2 were 52-week, phase 3, double-blinded trials that randomized patients 1:2:1 to placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. At week 52, eligible patients enrolled in POETYK LTE and received open-label deucravacitinib. Mean changes from baseline in laboratory parameters, laboratory adverse events (AEs), and laboratory AEs resulting in discontinuation were evaluated over 3 years.</p><p><strong>Results: </strong>A total of 1519 patients received one or more doses of deucravacitinib across trials. Total exposure over 3 years was 3294.3 person-years. No clinically relevant mean changes were observed in laboratory parameters. Grade ≥ 3 laboratory AEs were infrequent during the 1-year period, with incidence rates remaining stable in patients treated with deucravacitinib through 3 years. Most laboratory AEs remained at the same grade; shifts to higher grades were infrequent, with most increases being to grade ≤ 2. Discontinuations due to laboratory AEs were rare.</p><p><strong>Conclusions: </strong>Deucravacitinib did not result in clinically meaningful changes in laboratory parameters over 3 years, including changes seen with Janus kinase (JAK) 1,2,3 inhibitors. Grade ≥ 3 laboratory AEs and discontinuations were rare.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, POETYK PSO-1 (NCT03624127), POETYK PSO-2 (NCT03611751), POETYK LTE (NCT04036435).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1025-1035"},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generalized Pustular Psoriasis Brazilian Experts Survey: Challenges in Disease Management.","authors":"Ricardo Romiti, André V E de Carvalho, Cinara P C C Soares, Gleison Duarte","doi":"10.1007/s13555-025-01392-4","DOIUrl":"https://doi.org/10.1007/s13555-025-01392-4","url":null,"abstract":"<p><strong>Introduction: </strong>Generalized pustular psoriasis (GPP) is a rare and severe form of psoriasis. Diagnosis involves several steps due to its rarity and the similarity to other pustular skin conditions. There is a lack of standardized guidelines for managing patients. The objective of this survey was to understand how Brazilian dermatologists manage GPP.</p><p><strong>Methods: </strong>Three dermatologists, authors of this study, compiled a list of 57 Brazilian dermatologists who had treated patients with GPP in the last 5 years. A questionnaire composed of 28 questions about diagnosis, treatment, and follow-up of patients with GPP was sent to all dermatologists listed.</p><p><strong>Results: </strong>A total of 32 dermatologists answered the survey. Most were female, had more than 15 years of clinical practice, and had treated at least 3 patients in the last 5 years. The diagnosis was based on the presence of pustules, worsening skin lesions, and erythema. More than half of the participants cited inflammatory markers used for screening. Triggering factors for flares included steroid withdrawal, infection, and stress. Most of them reported that their patients experienced at least one flare per year, lasting 2-4 weeks. Pustules are the first sign of resolution and scaling skin could last more than 6 months. Hospitalization was considered common or very common, often lasting more than 1 week. During GPP flares, the most recommended treatments were cyclosporine. For residual disease treatment, retinoids were the most cited. In addition, 63% of dermatologists think that the options to resolve flares are too slow and 66% consider that options do not prevent new flares.</p><p><strong>Conclusions: </strong>GPP is a challenging disorder. In Brazil, Brazilian patients with GPP often require longer hospitalization when compared with Europe and USA. A local consensus on GPP management is urgently needed to establish the goals and the standard of care for these patients.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}